23:41 , Feb 7, 2019 |  BC Innovations  |  Finance

Pharma ventures earlier

Facing the squeeze from inside and out, at least three corporate venture arms are revamping operations to increase their foothold in earlier and riskier investment opportunities. From one side, the move reflects the growing reliance...
17:59 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Huntington’s disease (HD) Cell culture and fruit fly studies suggest promoting USP12 expression could help treat HD. In rat primary neurons expressing an HD-related mutant HTT fragment and induced pluripotent stem (iPS) cell-derived neurons...
18:19 , Oct 18, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers; tissue markers CSF levels of mutant HTT, and CSF or plasma levels of NEFL , could help diagnose HD and differentiate between manifest and premanifest disease. In 20 premanifest HD patients, 40...
18:05 , Oct 12, 2018 |  BC Week In Review  |  Company News

Roche gets option to Ionis' antisense dry AMD candidate

Roche (SIX:ROG; OTCQX:RHHBY) will pay Ionis Pharmaceuticals Inc. (NASDAQ:IONS) $75 million up front for an option to develop and commercialize IONIS-FB-LRx, a ligand-conjugated antisense (LICA) oligonucleotide targeting complement factor B (CFB). The partners plan to...
19:12 , Oct 10, 2018 |  BC Extra  |  Company News

Roche gets option to Ionis' antisense dry AMD candidate

Roche (SIX:ROG; OTCQX:RHHBY) will pay Ionis Pharmaceuticals Inc. (NASDAQ:IONS) $75 million up front for an option to develop and commercialize IONIS-FB-LRx, a ligand-conjugated antisense (LICA) oligonucleotide targeting complement factor B (CFB). The partners plan to...
01:50 , Sep 14, 2018 |  BC Innovations  |  Targets & Mechanisms

Repeat offenders

Dozens of intractable DNA repeat-driven diseases could boil down to a common problem: disrupted boundaries between chromatin domains, according to a study from the University of Pennsylvania. The results present new opportunities for diseases like...
20:10 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Huntington’s disease (HD) Mouse studies identified a PPP1R15B inhibitor that could help treat HD. Chemical synthesis and in vitro testing of guanabenz analogs yielded a compound that bound PPP1R15B with a K d of...
15:42 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Huntington's disease (HD) Cell culture and mouse studies suggest N6-furfuryladenine could help treat HD by promoting HTT phosphorylation. Screening of commercially available natural products in phosphorylation assays in a mouse striatal neuron cell line...
16:29 , May 4, 2018 |  BC Week In Review  |  Clinical News

uniQure reports preclinical data for Huntington's disease candidate

uniQure N.V. (NASDAQ:QURE) reported preclinical data showing that AMT-130 decreased mutant huntingtin (HTT) protein in animal models of Huntington's disease. Data were presented at the American Academy of Neurology meeting in Los Angeles. In a...
16:17 , May 4, 2018 |  BC Week In Review  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million on May 3 in a follow-on through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright &...